SIR-T B7-H3

SIR-T B7-H3 is an investigational cell therapy being developed by Angeles Therapeutics for the treatment of solid tumors. It utilizes the company's proprietary Synthetic Intramembrane Receptor (SIR-T) platform, which is designed to enhance the recognition and elimination of cancer cells. The therapy specifically targets B7-H3 (CD276), a transmembrane protein that is highly expressed in various cancers and is associated with immune evasion and poor clinical outcomes. By engineering T cells with SIR-T receptors specific to B7-H3, the therapy aims to provide a potent and selective anti-tumor response. It is currently in the discovery and preclinical stages of development.